Descovy (Emtricitabine/Tenofovir Alafenamide) for HIV: Complete Guide

Descovy (emtricitabine 200 mg / tenofovir alafenamide 25 mg) is a once-daily single-tablet regimen for HIV-1 treatment in adults and adolescents ≥35 kg. It combines two NRTIs with improved renal/bone safety vs. tenofovir disoproxil fumarate (TDF).

Indications

  • HIV-1 treatment: In combination with other antiretrovirals (e.g., integrase inhibitors, NNRTIs, boosted PIs).
  • HIV-1 PrEP: Descovy is not approved for PrEP (use Truvada or Apretude).

Key Advantages vs. TDF-Containing Regimens

  • Renal safety: 90% lower tenofovir plasma exposure → less proximal tubulopathy, Fanconi syndrome, eGFR decline.
  • Bone safety: Less BMD loss at spine/hip; fewer fractures in trials.
  • Smaller tablet: Better adherence potential.

Dosing & Administration

  • One tablet daily, with or without food.
  • No dose adjustment for eGFR ≥30 mL/min.
  • Not recommended if eGFR <30 (insufficient data).
  • Take consistently; missed doses → resistance risk.

Common Side Effects (≥2%)

  • Nausea, diarrhea, headache, fatigue, abnormal dreams, rash.
  • Weight gain (class effect with INSTI combinations).

Serious Risks

  • Lactic acidosis + severe hepatomegaly with steatosis: Rare, life-threatening. Higher risk in females, obesity, prolonged NRTI exposure.
  • Renal impairment: Monitor eGFR, UACR, serum phosphate periodically.
  • HBV flare: If co-infected, discontinuing Descovy can cause severe hepatitis. Test for HBV before initiation.
  • IRIS: Immune reconstitution inflammatory syndrome after ART initiation.

Major Drug Interactions

  • Do not co-administer with: Other tenofovir/emtricitabine products, adefovir, didanosine.
  • Caution with: NSAIDs, acyclovir, valacyclovir, ganciclovir, valganciclovir, aminoglycosides (additive nephrotoxicity).
  • CYP3A4/P-gp interactions: TAF is a substrate; strong inducers (rifampin, carbamazepine, St. John's wort) ↓ levels. Strong inhibitors generally safe but monitor.

Monitoring

  • HIV-1 RNA q3–6mo (goal: undetectable <50 copies/mL).
  • CD4 count q3–6mo initially.
  • eGFR, UACR, serum phosphate q6–12mo.
  • BMD (DEXA) if risk factors.
  • Fasting glucose, lipids annually.

Special Populations

  • Pregnancy: Sufficient data support use; preferred NRTI backbone per DHHS guidelines.
  • Adolescents ≥35 kg: Approved.
  • Hepatic impairment: No dose adjustment (Child-Pugh A/B); avoid Child-Pugh C.

Cost & Access

  • Wholesale: ~$2,000–$2,200/month.
  • Gilead Advancing Access, copay cards, patient assistance programs.
  • Generic entry expected post-2025 (patent landscape complex).

Descovy is a preferred NRTI backbone for HIV treatment, offering superior renal/bone safety. Not for PrEP. Requires combination therapy and regular monitoring.

HIV & AIDS - Related Articles